Research Portfolio

Funding Opportunities

Join our Mailing List
Join our mailing list to be notified of new funding opportunities.

Your Email

To receive information about funding opportunities, events, and program updates.



SAR Studies of Novel antitumor Agents for Lung Carcinomas

Institution: University of California, San Diego
Investigator(s): Michael Kelner, M.D., M.S.
Award Cycle: 1995 (Cycle 4) Grant #: 4RT-0226 Award: $403,338
Subject Area: Cancer
Award Type: Research Project Awards
Abstracts
Publications

Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells: unusually high sensitivity of ERCC2 and ERCC3 DNA helicase deficient mutants in comparison to other chemotherapeutic agents
Periodical: Biochemical Pharmacology Index Medicus:
Authors: Kelner MJ, McMorris L, Estes M, et al ART
Yr: 1994 Vol: 48 Nbr: 2 Abs: Pg: 403-409

Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents
Periodical: Anticancer Research Index Medicus:
Authors: Kelner MJ, McMorris TC, Estes L, et al ART
Yr: 1995 Vol: 15 Nbr: 3 Abs: Pg: 867-872

In vitro and in vivo studies on the anticancer activity of dehydroilludin M
Periodical: Anticancer Research Index Medicus:
Authors: Kelner MJ, McMorris TC, Taetle R ART
Yr: 1995 Vol: 15 Nbr: 3 Abs: Pg: 873-878

Efficacy of Acylfulvene Illudin analogs against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents retention of activity against various phenotypes.
Periodical: Cancer Research Index Medicus:
Authors: Kelner MJ, McMorris TC, Estes L, et al ART
Yr: 1995 Vol: 55 Nbr: 21 Abs: Pg: 4936-4940

Acylfulvenes, a new class of potent antitumor agents
Periodical: Experientia Index Medicus:
Authors: McMorris TC, Kelner MJ, Wang W, Diaz MA, Estes LA, Taetle R ART
Yr: 1996 Vol: 52 Nbr: (1) Abs: Pg: 75-80

Efficacy of HMAF (MGI-114-02) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents
Periodical: Investigational New Drugs Index Medicus:
Authors: Kelner MJ, McMorris TC, Estes L, et al ART
Yr: 1996 Vol: 14 Nbr: Abs: Pg: 161-167

Hydroxymethylacylfulvene: an Illudin derivative with superior antitumor properties
Periodical: Journal of Natural Products Index Medicus:
Authors: McMorris TC, Kelner MJ, Wang W, et al ART
Yr: 1996 Vol: 59 Nbr: Abs: Pg: 896-899

Characterization of cellular accululation and toxicity of Illudin S in sensitive and non-sensitive tumor cells
Periodical: Cancer Chemotherapy and Pharmacology Index Medicus:
Authors: Kelner MJ, McMorris TC, Montoya MA, et al ART
Yr: 1997 Vol: 40 Nbr: Abs: Pg: 65-71

Characterization of Acylfulvene histiospecific toxicity in human tumor cell lines
Periodical: Cancer Chemotherapy and Pharmacology Index Medicus:
Authors: Kelner MJ, McMorris TC, Montoya MA, et al ART
Yr: 1998 Vol: 41 Nbr: Abs: Pg: 237-242

Reaction of antitumor hydroxymethylacylfulvene (HMAF) with thiols
Periodical: Tetrahedron Letters Index Medicus:
Authors: McMorris TC, Yu J, Estes LA, Kelner MJ ART
Yr: 1997 Vol: 53 Nbr: Abs: Pg: 14579-14590

Efficacy of MGI 114 (6-hydroxymethylfulvene, HMAF)against the mdrI/gp170 Metastatic MV522 lung carcinoma xenograft
Periodical: European Journal of Cancer Index Medicus:
Authors: Kelner MJ, McMorris TC, Estes L, et al ART
Yr: 1998 Vol: 34 Nbr: Abs: Pg: 908-913